AJH: Clinical outcomes of MRD recurrence and role of therapeutic interventions after MRD-negative remission in AML patients
Time of Update: 2022-09-20
For patients with acute myeloid leukemia (AML), the cure rate is only 40-50% even if complete remission (CR) can be achieved after first-line therapy, confirming that many patients may have persistent
Inventory of the pathogenesis of AIDS and its related drugs
Time of Update: 2022-08-15
2 Anti-HIV/AIDS Drug Class 1 Reverse Transcriptase Inhibitors HIV is a retrovirus whose replication process relies on a unique enzyme, reverse transcriptase (RT), which reverse transcribes viral RNA into DNA provirus , so reverse transcriptase inhibitors can effectively inhibit the replication of the virus, is the earliest clinical application of anti-HIV/AIDS drugs .
"Science": It's the pot of the virus again
Time of Update: 2022-01-24
At least a large number of serum samples have been tested to point to a possible suspect - EBV (Epstein-Barr virus), which belongs to the Herpesviridae family of lymphotropic viruses and specifically attacks B cells .
Genxi Bio will announce the preclinical results of CD19/CD7 dual-targeting allogeneic CAR-T candidate product GC502 in ASH2021
Time of Update: 2021-11-14
S. Recently, Genxi Biotechnology Group (NASDAQ: GRCL) ; Referred to as "Genxi Bio"), a global clinical-stage biopharmaceutical company dedicated to the development of efficient and economical cell therapy for cancer treatment, today announced that it will be in the form of an electronic poster during the 63rd American Society of Hematology (ASH) annual meeting Announced the preclinical research data of its allogeneic chimeric antigen receptor (CAR) T cell therapy candidate product GC502 for the treatment of B cell malignancies .
Hengrui Medicine's 1.3 billion innovative drug Punaburin will be another wealth code
Time of Update: 2021-10-22
Figure 2 The inhibitory activity of punabulin on tumor cell lines and drug-resistant tumor cell linesIn 2011, Professor Hayashi summarized the structure-activity relationship of punabrine modified by phenylahistin (see Figure 3): 1.
Clin Transl Med: This is also ok
Time of Update: 2021-03-24
Mesenchymal stromal cells (MSC) are expected to be effective in the treatment of new coronary pneumonia, especially for critically ill patients.
Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.
Orphan Drug Weekly | Selective IL-2 agonists and other 4 research therapies are shortlisted
Time of Update: 2021-03-21
Drug: Nemvaleukin alfaR&D company: AlkermesTreatment of disease: mucosal melanoma (mucosal melanoma)Introduction: Nemvaleukin alfa is an innovative engineering fusion protein under research, which is composed of modified interleukin-2 (IL-2) and a high-affinity IL-2α receptor chain, designed to selectively amplify tumor-killing effects Immune cells, while avoiding activating immunosuppressive cells.
Nat Commun: Single-cell analysis reveals different immune conditions for transplanted tumors and primary sarcoma and affects the effectiveness of immunotherapy
Time of Update: 2020-12-31
, however, most preclinical immunotherapy studies focused on transplant tumor models, showing higher cure rates after combined immuno-checkpoint blocking and RT.
tumors and treatments promoted the remodeling of bone marrow cells, and researchers further identified tumor-immersion-related immune cells in transplant tumors and primary tumors, and revealed significant differences in their immune status.
FDA approves Danyelza for bone or bone marrow recurrence or recurring neuroblastoma
Time of Update: 2020-12-15
danyelza can be used in combination with granulocyte macrophage collection stimulation factors (GM-CSF) in adult and child patients with bone or bone marrow recurrence or refrmmune high-risk neuroblastoma.
45 percent of the 22 patients treated in the study 201, 30 percent had DOR for six months or more, according to the FDA.
The immunoasive profile of leukemia predicts the benefits of drug resistance and immunotherapy
Time of Update: 2020-07-21
By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), the researchers identified a new immune category for the disease, which can predict the possibility of drug resistance and positive response to immunotherapy.
AstraZeneca sold small molecule brensocatib approved by FDA breakthrough therapy
Time of Update: 2020-06-26
NCFBE is a serious chronic lung disease that causes permanent expansion of the bronchial tube due to the recurrence of infection, inflammation and pulmonary tissue damage The disease is typically char
Domestic second! Watson Bio Divalent HPV Vaccine Declared for Listing
Time of Update: 2020-06-26
Guide: Global sales of the HPV vaccine in 2019 total about $3.8 billion, according to the annual reports of GSK and Mercado On June 15, , Watson Bio announced that its controlling subsidiary Shanghai
Change abnormal gene expression, bet inhibitor, phase 2 clinical positive
Time of Update: 2019-11-07
Today, constellation pharmaceuticals announced that its selective bet inhibitor cpi-0610 showed good clinical activity in a phase 2 clinical trial called manifest to treat patients with myelofibrosis
Cell stem cell: reveal the new mechanism of maintaining leukemia stem cells! It is expected to strike cancer stem cells completely
Time of Update: 2019-04-28
April 28, 2019 / bioin / - most chronic myeloid leukemia patients can be treated with tyrosine kinase inhibitors These drugs are very effective, can produce deep remission and prolong survival However
The concept of superfine pulverizer and the selection of pulverizer
Time of Update: 2014-11-03
Superfine grinding technology is a new technology developed in the world in the past 20 years The so-called ultra-fine comminution refers to the use of mechanical or hydrodynamic methods to overcome t